Detalhe da pesquisa
1.
Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatment.
Pharm Stat;
21(3): 612-624, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34997685
2.
InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations.
Respir Res;
22(1): 130, 2021 Apr 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33910578
3.
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.
Am J Respir Crit Care Med;
202(9): 1237-1243, 2020 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32584168
4.
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med;
201(12): 1508-1516, 2020 06 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32162970
5.
Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis.
Respir Res;
21(1): 5, 2020 Jan 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31907054
6.
Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary disease.
Respir Res;
20(1): 195, 2019 Aug 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31443653
7.
Blood eosinophils and inhaled corticosteroid/long-acting ß-2 agonist efficacy in COPD.
Thorax;
71(2): 118-25, 2016 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26585525
8.
Blood eosinophils as a marker of response to inhaled corticosteroids in COPD.
Eur Respir J;
47(5): 1374-82, 2016 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26917606
9.
A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial.
Eur Respir J;
58(3)2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34385263
10.
Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Respir Res;
16: 25, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25849223
11.
Misinterpretation of time-to-first event curves can lead to inappropriate treatment.
Eur Respir J;
54(3)2019 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31488584
12.
IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial.
J Allergy Clin Immunol Glob;
1(4): 198-208, 2022 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37779541
13.
Number needed to treat: enigmatic results for exacerbations in COPD.
Eur Respir J;
47(1): 353-4, 2016 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26721973
14.
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
Int J Chron Obstruct Pulmon Dis;
16: 1925-1938, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34194225
15.
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.
ERJ Open Res;
7(1)2021 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33718490
16.
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial.
Pulm Ther;
7(1): 101-118, 2021 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33201438
17.
InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
Chronic Obstr Pulm Dis;
8(1)2021 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33156982
18.
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Lancet Respir Med;
7(9): 745-756, 2019 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31281061
19.
Developing tools for the safety specification in risk management plans: lessons learned from a pilot project.
Pharmacoepidemiol Drug Saf;
17(5): 445-54, 2008 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18383441
20.
Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.
Int J Chron Obstruct Pulmon Dis;
13: 3669-3676, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30464449